GI Innovation Join Forces with Merck to Evaluate GI-102 Plus Keytruda for Treating Various Cancers
Shots:
- GI Innovation has entered into a clinical trial collaboration & supply agreement with Merck to assess GI-102 + Keytruda for treating immunotx.-resistant liver cancer, melanoma & RCC. It has previously partnered for GI-101A with Merck
- Combination will be assessed under the P-II study to treat the 3 indications in patients resistant to immuno-oncology treatments. Study of GI-102 alone has achieved an ORR of 42.9% (3 PRs) in melanoma patients and tumor regression in 60% of mice in non-clinical liver cancer model
- The US sites such as Mayo Clinic (campuses in Rochester, Florida & Arizona), Cleveland Clinic & Memorial Sloan Kettering Cancer Center along with 14 South Korean hospitals will participate in the trial
Ref: Businesswire | Image: GI Innovation & Merck
Related News:- Roche’s Tecentriq SC Receives the EC’s Approval for Treating Various Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
